PT-141 (Bremelanotide)

PT-141 (Bremelanotide) Research Peptide

PT-141, also known as Bremelanotide, is a synthetic cyclic peptide intended for laboratory, analytical, and scientific research applications.

Bremelanotide is scientifically classified as a melanocortin receptor agonist. This makes PT-141 relevant to controlled research investigating melanocortin receptor systems, peptide–receptor interactions, neuroendocrine signaling, molecular pathways, and structure–activity relationships. FDA’s substance database recognizes PT-141 as a synonym for bremelanotide.

Laboratory research involving PT-141 may examine:

• Melanocortin receptor signaling
• Peptide–receptor interactions
• Neuroendocrine research pathways
• Molecular signaling mechanisms
• Cyclic peptide characterization
• Structure–activity relationships
• Peptide stability studies
• Analytical method development
• In-vitro experimental models
• Comparative peptide research

Any findings from experimental models should be interpreted within their specific research context and not as evidence that a research-grade PT-141 product is safe or effective for human use.

Product Information

• Product: PT-141
• Alternative Name: Bremelanotide
• Classification: Synthetic cyclic research peptide
• Primary Research Area: Melanocortin receptor research
• Research Applications: Molecular, biochemical, receptor, and neuroendocrine studies
• Intended Setting: Laboratory, analytical, and scientific research
• Supplier: Peptides R US

Important FDA Regulatory Distinction

Bremelanotide is also the active ingredient in the FDA-approved prescription product Vyleesi, which received approval under a specific New Drug Application in 2019. FDA identifies Vyleesi as a melanocortin receptor agonist with a specific approved formulation, labeling, indication, manufacturing process, and prescription-use requirements.

That approval does not mean that a PT-141 research product sold by Peptides R US is FDA approved, therapeutically equivalent to Vyleesi, or approved for the same use.

The product page should therefore avoid representing this research material as:

• FDA approved
• Generic Vyleesi
• Equivalent to Vyleesi
• A prescription treatment
• Intended to improve sexual performance
• Intended to treat any human medical condition

FDA’s approved labeling specifically states that Vyleesi itself is not indicated to enhance sexual performance, further underscoring the importance of keeping a research-material listing separate from claims associated with prescription use.

Research Use Only

This product is offered solely for legitimate laboratory, analytical, and scientific research purposes.

It is not intended for human or veterinary consumption or administration and is not intended to diagnose, treat, cure, mitigate, or prevent any disease or medical condition.

No dosage, injection, reconstitution-for-human-use, sexual-performance, therapeutic, or clinical-use instructions are provided or implied.